Business Context and Reporting Period
Company: Incyte Genomics, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2002
Business Overview: Incyte operates as a single segment focused on drug discovery and development products and services. The company holds a large portfolio of patents covering human genes and utilizes genomic databases and intellectual property licenses to assist pharmaceutical and biotechnology researchers. During 2001, the company executed a strategic restructuring, exiting custom genomics activities (microarrays, sequencing, clone products) to focus on therapeutic discovery and information products.
Key Financial Metrics
| Metric (in thousands) | Q1 2002 | Q1 2001 |
|---|---|---|
| Revenues | $29,014 | $51,121 |
| Operating Loss | $(18,897) | $(21,399) |
| Net Loss | $(13,441) | $(10,312) |
| Net Loss Per Share (Basic/Diluted) | $(0.20) | $(0.16) |
| Cash and Cash Equivalents | $99,156 | $114,689 |
| Marketable Securities | $392,554 | $N/A |
| Total Current Assets | $547,441 | $N/A |
| Total Liabilities | $245,436 | $N/A |
| Convertible Subordinated Notes | $179,137 | $N/A |
| Accumulated Deficit | $(281,580) | $(N/A) |
Liquidity: As of March 31, 2002, the company held $491.7 million in cash, cash equivalents, and marketable securities. Net cash used in operating activities was $6.0 million, while investing activities provided $59.1 million primarily due to the net sale of marketable securities.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 43% to $29.0 million from $51.1 million. This was driven by the exit of custom genomics product lines (which contributed $14.1 million in Q1 2001 vs. $2.0 million in Q1 2002) and lower licensing revenues.
- Expense Reduction: Total costs and expenses decreased 34% to $47.9 million from $72.5 million. Research and development expenses dropped 39% to $33.7 million, and SG&A expenses fell 15% to $14.2 million, reflecting the restructuring and elimination of exited activities.
- Operating Loss Improvement: Despite lower revenues, the operating loss narrowed to $18.9 million from $21.4 million due to significant cost reductions.
- Net Loss Increase: Net loss increased to $13.4 million from $10.3 million. The prior year period included an extraordinary gain of $2.4 million and a cumulative effect of accounting change gain of $2.3 million, which were absent in the current period.
- Balance Sheet: Cash and cash equivalents increased significantly from $43.4 million at year-end 2001 to $99.2 million, driven by net proceeds from the sale of marketable securities.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management expects to incur losses in 2002 and future periods as it invests heavily in therapeutic discovery and development programs. The company believes its existing capital resources are adequate for at least the next twelve months. Operating expenses are expected to be lower in 2002 compared to 2001, reflecting the restructuring, though spending on therapeutic discovery is increasing.
Unusual Items
- Restructuring: In Q4 2001, the company recorded a non-recurring charge of $130.4 million related to restructuring and asset impairments ($55.6 million restructuring, $68.7 million goodwill/intangibles impairment, $6.1 million long-lived asset impairment). This included the termination of approximately 400 employees and the exit of microarray and sequencing services.
- Subsequent Event: In April 2002, the company repurchased $6.7 million of convertible subordinated notes, recognizing a $1.9 million extraordinary gain.
Risks and Contingencies
- Litigation: The company is engaged in significant patent litigation with Invitrogen Corporation. Invitrogen sued Incyte for patent infringement in October 2001; Incyte filed counterclaims alleging infringement of 13 of its patents. The company expects substantial legal costs and cannot estimate potential losses. A settlement with Affymetrix was reached in December 2001.
- Debt Obligations: The company has $179.1 million in convertible subordinated notes due in 2007. Interest payments are approximately $9.7 million annually. The company has a deficiency of earnings available to cover fixed charges.
- Profitability: The company has an accumulated deficit of $281.6 million and expects to remain unprofitable as it transitions from information products to therapeutic drug development.
Investor Verification Checklist
- Litigation Exposure: Verify the status and potential financial impact of the ongoing patent infringement lawsuits with Invitrogen and the appeal regarding Stanford University patents.
- Cash Burn Rate: Monitor the rate of cash consumption given the shift to capital-intensive therapeutic discovery and the lack of near-term profitability.
- Debt Covenants: Review the terms of the $179.1 million convertible notes, specifically redemption triggers and conversion prices ($67.42/share).
- Revenue Mix: Assess the sustainability of revenue from database agreements and licensing as the company winds down legacy custom genomics services.
- Restructuring Completion: Confirm the final costs associated with the 2001 restructuring, including lease exit costs and severance payments.